Entrada Therapeutics (TRDA) announced it had received authorization from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency, MHRA, and Research Ethics Committee for its Clinical Trial of an Investigational Medicinal Product to initiate ELEVATE-44-201, a Phase 1/2 multiple ascending dose, MAD, clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy, DMD, in patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRDA: